Thanks posters above for clarifying. Sounds like it could be more of a distortionary threat then.
It would be a shame for the patient if this initiative redirected investment toward less effective but higher NPAT biotechs with new patents in similar spaces. Gov might need to think it through a bit harder.
General Comments / Chat, page-2855
-
- There are more pages in this discussion • 8,434 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
-0.030(1.94%) |
Mkt cap ! $260.6M | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.57 | $1.50 | $33.68K | 22.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 190 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 2472 | 3 |
View Market Depth
| Last trade - 12.21pm 19/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |